Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
Quant Imaging Med Surg ; 13(1): 441-448, 2023 Jan 01.
Article in English | MEDLINE | ID: mdl-36620149

ABSTRACT

Background: Hemorrhoids are a common benign disorder that can require surgery for treatment. Aluminum potassium sulfate and tannic acid (ALTA) have been used as a sclerotherapy agent that induces noninvasive sclerosis and regression of hemorrhoids without surgery. However, there is no objective index for determining its effectiveness. In this study, we prospectively investigated the usefulness of our method as an objective indicator of the effectiveness of ALTA sclerotherapy. Methods: From April 2015 to April 2019, 241 patients underwent ALTA sclerotherapy. We standardized a simple evaluation method using the lumen of the lower rectum as observed through a clear plastic proctoscope. Patients' hemorrhoids were evaluated preoperatively and their subjective satisfaction with treatment by our new method was evaluated on postoperative day 7. Results: Our method showed that among patients who lost the rectal lumen before treatment, the lumen was reacquired after ALTA sclerotherapy in 96.1% (224/233). McNemar test showed the effect of ALTA sclerotherapy to be significantly associated with lumen gain [κ value, 0.0027; 95% confidence interval (CI): 0.0001-0.0052], P<0.001]. Patients' subjective satisfaction with the treatment was significantly higher in the group reacquiring the lumen (Fisher's exact test, P=0.0186). Among those patients needing re-treatment, 59.4% (19/32) had lost their lumen during follow-up [mean difference, 0.578; standard deviation (SD): 0.502, P<0.001]. Conclusions: Our simple method using a clear plastic proctoscope could objectively indicate the effect of ALTA sclerotherapy and patients who needed re-treatment on losing their lumen during follow-up. We believe this method is highly advantageous for patients, can advocate the concept of the hemorrhoid shrinking sign, and will contribute to the development of new indication criteria for ALTA sclerotherapy.

2.
Oxf Med Case Reports ; 2021(11): omab117, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34909205
3.
Anticancer Res ; 34(8): 4121-5, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25075038

ABSTRACT

AIMS: The present study aimed to examine the feasibility of detecting vimentin (VIM) methylation in the serum of patients with colorectal cancer (CRC) and to determine the effectiveness of a relatively simple, inexpensive, and non-invasive test performed in combination with the conventional carcinoembryonic antigen analysis. MATERIALS AND METHODS: VIM methylation in the serum DNA of 242 patients with CRC was measured by a quantitative methylation-specific polymerase chain reaction. RESULTS: A significantly higher positive rate was obtained for VIM methylation than for carcinoembryonic antigen or carbohydrate antigen 19-9 in stage 0, I, and II patients. The combination of all three markers yielded similar sensitivity for patients with disease of stage 0: 57.1%, I: 36.1%, II: 45.2%, and III: 55.4%, whereas the sensitivity reached 85.7% for patients with stage IV disease. CONCLUSION: VIM methylation of serum DNA may be a useful marker for the early detection of CRC.


Subject(s)
Colorectal Neoplasms/genetics , DNA Methylation , Vimentin/genetics , Biomarkers, Tumor/blood , CA-19-9 Antigen , Carcinoembryonic Antigen/blood , Colorectal Neoplasms/blood , Colorectal Neoplasms/pathology , DNA/blood , Female , Humans , Male , Neoplasm Staging , Vimentin/metabolism
4.
Hepatogastroenterology ; 60(124): 781-3, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23732777

ABSTRACT

BACKGROUND/AIMS: Recently, it has been reported that HACE1, the E3 ubiquitin ligase, is epigenetically inactivated in human Wilms' tumors and HACE 1 expression was also down-regulated in colorectal and gastric carcinomas. METHODOLOGY: In this study, methylation status of the HACE1 gene was examined in primary carcinomas and the corresponding normal tissues derived from 27 patients with HCC using quantitative methylation-specific PCR (qMSP). RESULTS: Methylation of the HACE1 gene was detected in 18 out of the 27 (67%) HCCs, suggesting that the methylation of HACE1 was frequently observed in HCC. The clinicopathological data were then correlated with these results. In the value of serum AFP (α-fetoprotein), a significant difference was observed (p=0.0025). CONCLUSIONS: All stages of HCCs presented HACE1 methylation, indicating that the HACE1 gene has been methylated from the early stages of HCCs.


Subject(s)
Carcinoma, Hepatocellular/genetics , DNA Methylation , Liver Neoplasms/genetics , Ubiquitin-Protein Ligases/genetics , Aged , Female , Humans , Male , Middle Aged , Polymerase Chain Reaction
5.
Hepatogastroenterology ; 59(120): 2573-5, 2012.
Article in English | MEDLINE | ID: mdl-23178624

ABSTRACT

BACKGROUND/AIMS: Recently, we detected that UNC5C expression was downregulated in colon and gastric cancer. METHODOLOGY: In the present study, the methylation status of the UNC5C gene was examined in primary carcinomas and the corresponding normal tissues derived from 42 patients with HCC. RESULTS: Methylation of the UNC5C gene was detected in 11 out of the 42 (26%) HCCs, suggesting that the methylation of UNC5C was frequently observed in HCCs. The clinicopathological data were correlated with the methylation results. CONCLUSIONS: TNM stage 1 HCC presented UNC5C methylation, indicating that the UNC5C gene has been methylated from the early stages of HCC.


Subject(s)
Carcinoma, Hepatocellular/genetics , DNA Methylation , Liver Neoplasms/genetics , Receptors, Cell Surface/genetics , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/pathology , Female , Genetic Predisposition to Disease , Humans , Liver Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Netrin Receptors , Phenotype , Polymerase Chain Reaction
6.
Cancer Genet ; 205(11): 594-8, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23036697

ABSTRACT

Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare disease, and many cases are either benign neoplasms or low-graded malignancies; however, a few cases show rapid progressive clinical courses. No effective therapy has yet been established for WDPMP, and the molecular basis of WDPMP tumorigenesis has never been reported. This study shows the malignant transformation of WDPMP in a Japanese female patient, who was alive for 54 months after the initial diagnosis by a laparoscopic biopsy. A molecular analysis of single nucleotide polymorphisms (SNPs), which were located in the neurofibromatosis type 2 (NF2) gene, a tumor suppressor gene assigned to chromosome 22q12.3, revealed the loss of heterozygosity (LOH) of the NF2 gene. Furthermore, SNP analyses determined that LOH was observed in the IL17RA (22q11.1), CHECK2 (22q12.1), and SHANK3 (22q13.3) genes, thus suggesting that NF2 loss occurred through 22q deletions or monosomy 22. The LOH of the NF2 gene was observed in an early stage of WDPMP, thus indicating that LOH of the NF2 gene is an early molecular alteration, and NF2 loss is a molecular mechanism associated not only with malignant pleural mesothelioma, but also with WDPMP.


Subject(s)
E2F1 Transcription Factor/genetics , Genes, Neurofibromatosis 2 , Loss of Heterozygosity , Mesothelioma/genetics , Peritoneal Neoplasms/genetics , Aged , DNA Mutational Analysis , Fatal Outcome , Female , Histocytochemistry , Humans , Mesothelioma/pathology , Mesothelioma/surgery , Peritoneal Neoplasms/pathology , Polymorphism, Single Nucleotide
7.
Anticancer Res ; 32(5): 1757-62, 2012 May.
Article in English | MEDLINE | ID: mdl-22593457

ABSTRACT

BACKGROUND: Predictors of the response of colorectal cancer to chemotherapy remain poorly understood. We analyzed the mRNA expression levels of enzymes related to sensitivity to 5-fluorouracil derivatives in patients with colorectal cancer. PATIENTS AND METHODS: Danenberg tumor profile method (DTP) was used in order to measure mRNA expression levels of thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD), and thymidine phosphorylase (TYMP) from 180 patients with colorectal cancer. The relations of expression levels with clinicopathological factors and outcomes were studied. RESULTS: Higher TYMS expression was associated with greater age, DPYD expression with greater age, poorer differentiation and low invasion, and TYMP expression with poorer differentiation and lack of peritoneal metastasis. DPYD expression positively correlated with TYMP expression. In patients with stage IV disease, high DPYD or TYMP expression was associated with poor outcomes. CONCLUSION: mRNA expression of TYMS, DPYD, and TYMP is associated with distinct characteristics and may be useful for predicting survival in patients with stage IV colorectal cancer.


Subject(s)
Colorectal Neoplasms/enzymology , Dihydrouracil Dehydrogenase (NADP)/genetics , Gene Expression Regulation, Neoplastic , Thymidine Phosphorylase/genetics , Thymidylate Synthase/genetics , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Female , Fluorouracil/therapeutic use , Humans , Male , Middle Aged , Neoplasm Staging , RNA, Messenger/analysis
8.
Anticancer Res ; 32(4): 1319-22, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22493364

ABSTRACT

BACKGROUND: Recently, the human deafness, autosomal dominant 5 gene, DFNA5, has frequently been detected in cancer tissues. The methylation status of the DFNA5 gene in colorectal cancer was examined and was compared to the clinocopathological findings. MATERIALS AND METHODS: Eighty-five tumor samples and corresponding normal tissues were obtained from patients with colorectal cancer who underwent surgery at our hospital. The methylation status of the DFNA5 gene in these samples was examined by quantitative methylation-specific PCR (qMSP). Subsequently, the clinicopathological findings were correlated with the methylation status of the DFNA5 gene. RESULTS: DFNA5 gene methylation was found in 29 (34%) out of the 85 colorectal carcinomas, suggesting that it was frequently observed in colorectal cancer. A significant correlation with methylation was observed for lymphatic vessel invasion and TNM stage (p=0.0268 and p=0.0189, respectively). CONCLUSION: DFNA5 might act as a tumor suppressor gene and DFNA5 gene methylation might play an important role in the development of colorectal cancer. Our data implicate DFNA5 gene methylation as a novel molecular biomarker in colorectal cancer.


Subject(s)
Colorectal Neoplasms/genetics , DNA Methylation , Receptors, Estrogen/genetics , Aged , Colorectal Neoplasms/pathology , Female , Humans , Male , Middle Aged
9.
Anticancer Res ; 32(3): 787-90, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22399594

ABSTRACT

In our previous study, we used quantitative methylation-specific polymerase chain reaction (qMSP) to examine the methylation status of tissue factor pathway inhibitor 2 (TFPI2) in the preoperative serum DNA of 215 colorectal cancer patients and found that TFPI2 was methylated in serum DNA from 39 of these patients. In this study, we examined postoperative serum DNA, obtained within one month after surgery from 38 out of the 39 patients and found that TFPI2 was methylated in the serum DNA of only 18 (47%) of these patients, suggesting that TFPI2 methylation in the serum of the remaining colorectal cancer patients was abolished by surgical tumor reduction. Next, we examined the correlation between the presence of TFPI2 methylation in postoperative serum DNA and residual cancer status after surgery. If R0 (no residual cancer) operations were successfully performed, TFPI2 methylation was not detected in postoperative serum. However, if R2 (obvious residual cancer) operations were performed, 17 (77%) out of 22 postoperative sera, still exhibited TFPI2 methylation. Taken together, our results confirm that detection of methylated TFPI2 in serum DNA was derived from colorectal cancer and could serve as a marker of surgical outcome.


Subject(s)
Colorectal Neoplasms/blood , DNA Methylation , DNA/blood , Glycoproteins/metabolism , Base Sequence , Colorectal Neoplasms/genetics , Colorectal Neoplasms/surgery , DNA Primers , Humans , Treatment Outcome
10.
Anticancer Res ; 32(3): 791-4, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22399595

ABSTRACT

AIM: Detection of gastric cancer using serum assay of vimentin methylation. METHODS: A quantitative methylation-specific polymerase chain reaction assay was used to detect vimentin gene (VIM) methylation in the serum of 71 patients with gastric cancer. RESULTS: Mean VIM methylation in cancer patients (0.304 ± 0.558) was significantly higher than that in healthy donors (0.011 ± 0.015, p=0.018). The sensitivity of VIM methylation (33.8%) was similar to the one of carbohydrate antigen 19-9 (CA19-9) (25.4%), higher than the one of carcinoembryonic antigen (CEA) (12.7%), and significantly higher than the sensitivity of both markers for patients with stage I and IV disease (p=0.010 and 0.044, respectively). At all stages, the sensitivity of a combination of markers was higher than the sensitivity of any in isolation marker and was similar for stages I, II and III, reaching 76.9% for stage IV disease. CONCLUSION: VIM methylation may represent a useful marker for the detection of tumor DNA in the serum of patients with gastric cancer.


Subject(s)
Stomach Neoplasms/blood , Vimentin/metabolism , Aged , Base Sequence , Case-Control Studies , DNA Primers , Female , Humans , Male , Methylation , Middle Aged , Polymerase Chain Reaction
11.
Gan To Kagaku Ryoho ; 39(2): 231-5, 2012 Feb.
Article in Japanese | MEDLINE | ID: mdl-22333633

ABSTRACT

We analyzed the relationship between Onodera's prognostic nutritional index(PNI), classified by serum albumin level, lymphocyte level, and clinicopathological features, in 46 patients with unresectable or recurrent colorectal cancer being treated with chemotherapy.Onodera 's PNI was distributed between 29.7 and 56.1(average 45.4±6.8 ).Onodera 's PNI showed a significant correlation with performance status and surgery before chemotherapy(p=0.002 and 0.002, respectively).Next, all patients were divided into two groups according to their Onodera's PNI values, based on the receiver operator characteristic curve.We found that Onodera's PNI showed a significant correlation with overall survival times(median survival time, 548 days(Onodera's PNI<47.8 ), 902 days(Onodera's PNI≥47.8 ), p=0.00065 ).This PNI could be a prognostic factor and a very useful objective screening tool for assessing the nutritional condition of those with unresectable or recurrent colorectal cancer being treated with chemotherapy.


Subject(s)
Antineoplastic Agents/therapeutic use , Colorectal Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/pathology , Female , Humans , Male , Middle Aged , Nutrition Assessment , Prognosis , Recurrence , Survival Rate
12.
Anticancer Res ; 31(11): 3835-8, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22110206

ABSTRACT

BACKGROUND: Methylation of tissue factor pathway inhibitor-2 (TFPI2) has been detected in the stool of colorectal cancer patients. Using quantitative methylation-specific polymerase chain reaction (qMSP), 39 out of 215 (18%) patients exhibited TFPI2 methylation in their serum DNA, suggesting that a significant number of methylated TFPI2 existed in colorectal cancer patients' sera. MATERIALS AND METHODS: Methylation status of the TFPI2 gene was examined in sera derived from 73 patients with gastric cancer using qMSP and the correlation between the methylation status and the clinicopathological findings was evaluated. RESULTS: Out of 73 serum samples, 7 (10%) exhibited TFPI2 methylation in their serum DNA by qMSP, suggesting that TFPI2 methylation existed in the serum of gastric cancer patients. After completion of qMSP analysis of all specimens, clinicopathological data were correlated with the molecular analysis. TFPI2 methylation was significantly more frequently found in serum of patients with lymph node metastasis (p=0.0040) and distant metastasis (p=0.0115). CONCLUSION: In principle, knowledge of the methylation status of a primary tumor is not required in advance in order to be able to detect circulating tumor DNA. Therefore, qMSP could be used as a cancer screening method.


Subject(s)
DNA Methylation , Glycoproteins/genetics , Stomach Neoplasms/blood , Stomach Neoplasms/genetics , Aged , Aged, 80 and over , Case-Control Studies , Early Detection of Cancer , Female , Flow Cytometry , Humans , Liver Neoplasms/blood , Liver Neoplasms/genetics , Liver Neoplasms/secondary , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Peritoneal Neoplasms/blood , Peritoneal Neoplasms/genetics , Peritoneal Neoplasms/secondary , Polymerase Chain Reaction , Prognosis , Stomach Neoplasms/diagnosis
13.
Anticancer Res ; 31(10): 3377-80, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21965749

ABSTRACT

BACKGROUND: Recently, we have reported an important role of epidermal growth factor-like domain 8 (EGFL8) in the progression of colorectal cancer (CRC) and documented EGFL8 to be a novel prognostic biomarker for this malignancy. However, the function of EGFL8 in the other human gastroenterological malignancies such as gastric cancer remains largely unknown. PATIENTS AND METHODS: EGFL8 expression in 53 cases of gastric cancer and the corresponding normal tissues were determined by quantitative real-time PCR and the EGFL8 down-regulation score for each patient was calculated. Subsequently, the correlations between EGFL8 down-regulation score and the clinicopathological features of gastric cancer were evaluated. RESULTS: EGFL8 expression was significantly lower in the gastric cancer tissues than the corresponding normal tissues (p=0.0001) and the down-regulation of EGFL8 was evident in 73.6% (39/53) of the gastric carcinomas. More importantly, EGFL8 down-regulation was correlated significantly with peritoneal dissemination (p=0.037) and high TNM stage (p=0.025) of gastric cancer. CONCLUSION: The down-regulation of EGFL8 might be a novel biomarker for advanced gastric cancer.


Subject(s)
Biomarkers, Tumor/genetics , Down-Regulation/genetics , Endothelial Growth Factors/genetics , Gene Expression Regulation, Neoplastic , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Aged , Biomarkers, Tumor/metabolism , Calcium-Binding Proteins , EGF Family of Proteins , Endothelial Growth Factors/metabolism , Female , Humans , Male , Middle Aged , Neoplasm Staging
14.
Anticancer Res ; 31(9): 2889-92, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21868534

ABSTRACT

BACKGROUND: Homeodomein only protein x (HOPX) gene methylation has frequently been detected in cancer tissues. The methylation status of the HOPX gene in colorectal cancer was examined and compared to the clinocopathological findings. MATERIALS AND METHODS: Eighty-nine tumor samples and corresponding normal tissues were obtained from colorectal cancer patients who underwent surgery at our hospital. The methylation status of the HOPX gene in these samples was examined by quantitative methylation-specific PCR (qMSP). Subsequently, the clinicopathological findings were correlated with the methylation status of the HOPX gene. RESULTS: HOPX gene methylation was found in 46 (52%) out of the 89 colorectal carcinomas, suggesting that it was frequently observed in colorectal cancer. A significant increase of methylation was observed in the poorly differentiated carcinomas (p=0.0049). CONCLUSION: HOPX gene methylation could play an important role for the development of colorectal cancer and is closely related to the histological type.


Subject(s)
Cell Differentiation , Colorectal Neoplasms/genetics , DNA Methylation , Genes, Homeobox , Aged , Base Sequence , Colorectal Neoplasms/pathology , DNA Primers , Female , Humans , Male , Middle Aged
15.
Cancer Lett ; 311(1): 96-100, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-21820798

ABSTRACT

We examined whether TFPI2 methylation can be used as a molecular marker for colorectal cancers by detecting TFPI2 methylation in colorectal cancer patients' sera by using quantitative methylation-specific polymerase chain reaction (qMSP). The qMSP analysis showed that 39 of 215 (18%) patients exhibited TFPI2 methylation in their serum DNA, suggesting that TFPI2 methylation frequently existed in colorectal cancer patients' sera. After completion of qMSP analysis, clinicopathological data were correlated with molecular data. TFPI2 methylation was significant in the sera of patients with large (p = 0.0022), poorly differentiated carcinoma (p = 0.0164), deep invasion (p = 0.0002), lymph node metastasis (p = 0.0147), or distant metastasis (p < 0.0001). Moreover, TFPI2 methylation was observed more frequently according to the progression of TNM stage, suggesting that serum TFPI2 methylation could be detected more easily in patients with advanced colorectal cancer. We also examined whether serum TFPI2 methylation would be useful in the detection of colorectal cancer, compared to the conventional tumor markers. Detection rates of colorectal cancer using the tumor markers TFPI2 methylation, CEA and CA19-9, in the serum were 18%, 33%, and 17%, respectively. In cases where we combined all three markers, the detection rate was 42%. High sensitivity of qMSP enables detection of smaller amounts of serum tumor DNA. In principle, the methylation status of a primary tumor is not required in advance to detect circulating tumor DNA, suggesting the potential of qMSP as a cancer screening method.


Subject(s)
Colorectal Neoplasms/blood , Colorectal Neoplasms/genetics , DNA Methylation , Glycoproteins/genetics , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Cell Differentiation , Colorectal Neoplasms/pathology , Female , Humans , Male , Middle Aged
16.
Anticancer Res ; 31(6): 2249-54, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21737648

ABSTRACT

BACKGROUND: In a previous study, we reported a critical role of epidermal growth factor-like domain 7 (EGFL7) in the metastasis of hepatocellular carcinoma (HCC) and documented it to be a prognostic biomarker as well as a potential therapeutic target for HCC. However, the role of EGFL8, the only known paralog of EGFL7, in human malignancies is currently unclear. PATIENTS AND METHODS: EGFL8 expression in 101 cases of colorectal cancer (CRC) patients was determined by quantitative reverse transcription-polymerase chain reaction and the clinicopathological features of the CRC patients were correlated with the EGFL8 down-regulation scores. In addition, the survival curve and Cox regression model were also employed to assess the prognostic value of EGFL8 down-regulation. RESULTS: EGFL8 was significantly decreased in CRC tissues (p<0.0001) and the down-regulation of EGFL8 was evidenced in 74.3% (75/101) of the CRC patients. EGFL8 down-regulation correlated significantly to distant metastasis (p=0.038) and high TNM stage (p=0.012) of CRC. The CRC patients with high EGFL8 down-regulation showed either poorer disease-free survival (p=0.0167) or poorer overall survival (p=0.0310) than those with low EGFL8 down-regulation. Multivariable analysis identified EGFL8 down-regulation as an independent prognostic factor for CRC patients (hazard ratio, 12.974; p=0.037). CONCLUSION: The reduced expression of EGFL8 is closely related to metastastic potential and poor prognosis of CRC, suggesting the down-regulation of EGFL8 as a novel prognostic biomarker for CRC patients.


Subject(s)
Biomarkers, Tumor/biosynthesis , Colorectal Neoplasms/metabolism , Endothelial Growth Factors/biosynthesis , Biomarkers, Tumor/genetics , Calcium-Binding Proteins , Case-Control Studies , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Down-Regulation , EGF Family of Proteins , Endothelial Growth Factors/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Prognosis
17.
Anticancer Res ; 31(3): 777-80, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21498695

ABSTRACT

BACKGROUND: Recently, metastasis associated with colon cancer 1 (MACC1) gene was identified by genome-wide search for differentially expressed genes in human colon cancer tissues and metastases. Previously, MACC1 expression was examined in colorectal carcinomas and gastric carcinomas and was found to show significant correlation with peritoneal dissemination. PATIENTS AND METHODS: In this study, MACC1 expression was analyzed in 60 samples (tumor and the surrounding non-tumorous liver tissue) collected from 30 patients with hepatocellular carcinoma (HCC) using quantitative real-time polymerase chain reaction (QRT-PCR). Results. MACC1 expression score (tumor:normal) in primary HCC was between 0.01 and 4.59 (average±SD=0.68±0.94). Subsequently, clinicopathological data were correlated with the MACC1 expression. It was found that MACC1 expression showed significant correlation with vascular invasion and α-fetoprotein level (p=0.034, p=0.0098, respectively). CONCLUSION: These results suggest that MACC1 is more frequently expressed in vascular invasive HCC and may serve as a new parameter for the prognostic prediction of HCC.


Subject(s)
Biomarkers, Tumor/metabolism , Blood Vessels/pathology , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Transcription Factors/metabolism , Aged , Biomarkers, Tumor/genetics , Carcinoma, Hepatocellular/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Liver Neoplasms/genetics , Male , Middle Aged , Neoplasm Invasiveness , Trans-Activators , Transcription Factors/genetics , alpha-Fetoproteins/metabolism
18.
Anticancer Res ; 31(4): 1289-91, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21508377

ABSTRACT

BACKGROUND: Recently, it was shown that the Vimentin gene, usually activated in mesenchymal cells, was highly methylated in colorectal carcinoma. MATERIALS AND METHODS: The methylation status of the Vimentin gene was examined in primary carcinomas and the corresponding normal tissues derived from 43 patients with hepatocellular carcinoma (HCC) using quantitative methylation-specific PCR (qMSP) and the correlation between the methylation status and the clinicopathological findings was evaluated. RESULTS: Aberrant methylation of the Vimentin gene was detected in 24 out of the 43 (56%) primary HCC. This result suggested that the aberrant methylation of the Vimentin gene was frequent in HCC. Subsequently, clinicopathological data were correlated with the methylation status. A significant difference was observed in the value of alpha-fetoprotein (AFP) (p=0.045), maximal tumor size (p=0.048) and TNM stage (p=0.043) between the methylation-positive and -negative cases. CONCLUSION: Aberrant methylation of Vimetin might be an early event in the course of hepatocarcinogenesis.


Subject(s)
Carcinoma, Hepatocellular/genetics , DNA Methylation , Gene Expression Regulation, Neoplastic , Liver Neoplasms/genetics , Vimentin/genetics , Aged , DNA, Neoplasm/genetics , Female , Humans , Male , Polymerase Chain Reaction , Prognosis , Promoter Regions, Genetic/genetics , alpha-Fetoproteins/genetics
19.
Anticancer Res ; 31(4): 1293-5, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21508378

ABSTRACT

BACKGROUND: Recently, it has been reported that oncostatin M receptor-ß (OSMR) is frequently methylated in primary colon cancer tissues, but not in normal tissues. We examined the methylation status of the OSMR gene in primary carcinomas and the corresponding normal tissues derived from 56 patients with colorectal cancer. PATIENTS AND METHODS: The methylation status of the OSMR gene was examined in primary carcinomas and corresponding normal tissues derived from 56 patients with colorectal cancer using quantitative methylation-specific PCR (qMSP), and the correlation between the methylation status and the clinicopathological findings was evaluated. RESULTS: Methylation of the OSMR gene was detected in 18 out of the 56 (32%) primary colon carcinomas. The clinicopathological data were then compared with the methylation results. A significant difference was observed in regard to the extent of tumour (p=0.0442). These results indicated that OSMR was more frequently methylated in non-invasive colorectal carcinomas. CONCLUSION: OSMR may act as a tumour suppressor in colorectal carcinoma and OSMR methylation may play an important role in non-invasive colorectal cancer.


Subject(s)
Colorectal Neoplasms/genetics , DNA Methylation , Gene Expression Regulation, Neoplastic , Oncostatin M Receptor beta Subunit/genetics , Adult , Aged , Aged, 80 and over , Colon/metabolism , Colon/pathology , DNA, Neoplasm/genetics , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Polymerase Chain Reaction , Prognosis , Promoter Regions, Genetic/genetics , Rectum/metabolism , Rectum/pathology , Young Adult
20.
Anticancer Res ; 31(1): 77-9, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21273583

ABSTRACT

BACKGROUND: Recently, it has been shown that the loss of the human histone acetyl transferase, TIP60, led to an accumulation of double-strand DNA breaks and has been linked to a growing number of cancer types. MATERIALS AND METHODS: TIP60 expression levels were examined in 46 gastric cancer samples using a quantitative real-time polymerase chain reaction (QRT-PCR). Subsequently, clinicopathological data were correlated with the TIP60 expression score. RESULTS: A down-regulation of the TIP60 gene was observed in 28 out of 46 (61%) specimens of primary gastric cancer. TIP60 down-regulation showed significant correlation with patient age (p=0.0224), depth of tumor invasion (p=0.0401) and lymph node metastasis (p=0.0481). CONCLUSION: The down-regulation of TIP60 is important for the malignant pathway of gastric carcinogenesis.


Subject(s)
Biomarkers, Tumor/genetics , Histone Acetyltransferases/genetics , Liver Neoplasms/genetics , Peritoneal Neoplasms/genetics , Stomach Neoplasms/genetics , Aged , Biomarkers, Tumor/metabolism , Down-Regulation , Female , Histone Acetyltransferases/metabolism , Humans , Liver Neoplasms/metabolism , Liver Neoplasms/secondary , Lymphatic Metastasis , Lysine Acetyltransferase 5 , Male , Peritoneal Neoplasms/metabolism , Peritoneal Neoplasms/secondary , Prognosis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...